Newsbenzinga
FDA Setback Clouds Timeline For Bright Minds Biosciences' Pediatric Epilepsy Trials
· Published
Article summary
The FDA places a partial clinical hold on Bright Minds Biosciences' Phase 2 epilepsy study after mouse toxicity and pediatric data concerns.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…